PDGFRA - Wiki-MPM

Novel	Interactant Symbol	Name	Associated Pathways Hide	Binding Drugs Hide	Associated Diseases Hide
Novel	AKT1	AKT serine/threonine kinase 1	Activation of BAD and translocation to mitochondria PIP3 activates AKT signaling PIP3 activates AKT signaling Downregulation of ERBB2:ERBB3 signaling Translocation of SLC2A4 (GLUT4) to the plasma membrane Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation MTOR signalling AKT phosphorylates targets in the cytosol AKT phosphorylates targets in the cytosol AKT phosphorylates targets in the nucleus Negative regulation of the PI3K/AKT network eNOS activation AKT-mediated inactivation of FOXO1A Integrin signaling Deactivation of the beta-catenin transactivating complex CD28 dependent PI3K/Akt signaling Co-inhibition by CTLA4 G beta:gamma signalling through PI3Kgamma Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA KSRP (KHSRP) binds and destabilizes mRNA VEGFR2 mediated vascular permeability TP53 Regulates Metabolic Genes Constitutive Signaling by AKT1 E17K in Cancer Interleukin-4 and Interleukin-13 signaling Regulation of TP53 Degradation Regulation of TP53 Activity through Acetylation Regulation of TP53 Activity through Association with Co-factors PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling Cyclin E associated events during G1/S transition Cyclin A:Cdk2-associated events at S phase entry PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 RAB GEFs exchange GTP for GDP on RABs RUNX2 regulates genes involved in cell migration Regulation of PTEN stability and activity Extra-nuclear estrogen signaling Negative regulation of NOTCH4 signaling FLT3 Signaling Regulation of localization of FOXO transcription factors Estrogen-dependent nuclear events downstream of ESR-membrane signaling KEAP1-NFE2L2 pathway SARS-CoV-2 targets host intracellular signalling and regulatory pathways Mitochondrial unfolded protein response (UPRmt) High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells Mechanical load activates signaling by PIEZO1 and integrins in osteocytes	ATP Arsenic trioxide Genistein Inositol 1,3,4,5-Tetrakisphosphate Resveratrol Archexin Enzastaurin Perifosine N-[2-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine 5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine	PTEN hamartoma tumor syndrome (PHTS), including: Cowden syndrome; Bannayan-Riley-Ruvalcaba syndrome; Proteus syndrome; Proteus-like syndrome
Novel	ALB	albumin	Platelet degranulation Recycling of bile acids and salts Heme biosynthesis Heme degradation Scavenging of heme from plasma Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) Post-translational protein phosphorylation HDL remodeling Cytoprotection by HMOX1 Aspirin ADME Prednisone ADME Ciprofloxacin ADME	Amsacrine Cefotaxime Phenol Norelgestromin Aniline Guaiacol Artenimol Silver Patent Blue
Novel	ARNT	aryl hydrocarbon receptor nuclear translocator	Regulation of gene expression by Hypoxia-inducible Factor PPARA activates gene expression Phase I - Functionalization of compounds Endogenous sterols Xenobiotics Aryl hydrocarbon receptor signalling NPAS4 regulates expression of target genes NPAS4 regulates expression of target genes
Novel	AURKA	aurora kinase A	APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 Regulation of PLK1 Activity at G2/M Transition SUMOylation of DNA replication proteins TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest Regulation of TP53 Activity through Phosphorylation FBXL7 down-regulates AURKA during mitotic entry and in early mitosis AURKA Activation by TPX2 Interaction between PHLDA1 and AURKA	Phosphonothreonine AT9283 CYC116 Alisertib SNS-314 Cenisertib Enzastaurin 4-(4-METHYLPIPERAZIN-1-YL)-N-[5-(2-THIENYLACETYL)-1,5-DIHYDROPYRROLO[3,4-C]PYRAZOL-3-YL]BENZAMIDE AKI-001 1-{5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl]-1,3-thiazol-2-yl}-3-[3-(trifluoromethyl)phenyl]urea 1-(5-{2-[(1-methyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)amino]ethyl}-1,3-thiazol-2-yl)-3-[3-(trifluoromethyl)phenyl]urea N-{3-[(4-{[3-(TRIFLUOROMETHYL)PHENYL]AMINO}PYRIMIDIN-2-YL)AMINO]PHENYL}CYCLOPROPANECARBOXAMIDE N-butyl-3-{[6-(9H-purin-6-ylamino)hexanoyl]amino}benzamide 2-(1H-pyrazol-3-yl)-1H-benzimidazole N-[3-(1H-BENZIMIDAZOL-2-YL)-1H-PYRAZOL-4-YL]BENZAMIDE Fostamatinib MK-5108 MLN8054
Novel	BECN1	beclin 1	ISG15 antiviral mechanism Macroautophagy Ub-specific processing proteases Translation of Replicase and Assembly of the Replication Transcription Complex Translation of Replicase and Assembly of the Replication Transcription Complex SARS-CoV-2 activates/modulates innate and adaptive immune responses Antigen Presentation: Folding, assembly and peptide loading of class I MHC RSV-host interactions	Estradiol Estradiol acetate Estradiol benzoate Estradiol cypionate Estradiol dienanthate Estradiol valerate
Novel	CAV1	caveolin 1	Triglyceride catabolism eNOS activation NOSTRIN mediated eNOS trafficking Thyroxine biosynthesis Basigin interactions Disassembly of the destruction complex and recruitment of AXIN to the membrane VEGFR2 mediated vascular permeability RHOA GTPase cycle Extra-nuclear estrogen signaling RHOB GTPase cycle RHOC GTPase cycle CDC42 GTPase cycle RAC1 GTPase cycle RAC2 GTPase cycle RHOD GTPase cycle RHOQ GTPase cycle RHOH GTPase cycle RHOG GTPase cycle RHOJ GTPase cycle RAC3 GTPase cycle RHOF GTPase cycle FOXO-mediated transcription of cell cycle genes RND3 GTPase cycle RND2 GTPase cycle RND1 GTPase cycle SARS-CoV-1 targets host intracellular signalling and regulatory pathways SARS-CoV-2 targets host intracellular signalling and regulatory pathways		Congenital generalized lipodystrophy (CGL)
Novel	CAV3	caveolin 3	Smooth Muscle Contraction Smooth Muscle Contraction		Limb-girdle muscular dystrophy (LGMD) Caveolinopathies, including: Limb-girdle muscular dystrophy (LGMD) 1C; Rippling muscle disease (RMD); Idiopathic hyperCKemia; Distal myopathy with decreased caveolin 3; Hypertrophic cardiomyopathy (HCM) Long QT syndrome, including: Romano-Ward syndrome; Jervell and Lange-Nielsen syndrome (JLNS)
Novel	CBL	Cbl proto-oncogene	Interleukin-6 signaling Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants Spry regulation of FGF signaling Regulation of KIT signaling EGFR downregulation TGF-beta receptor signaling activates SMADs Constitutive Signaling by EGFRvIII Negative regulation of FGFR1 signaling Negative regulation of FGFR2 signaling Negative regulation of FGFR3 signaling Negative regulation of FGFR4 signaling Negative regulation of MET activity PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis InlB-mediated entry of Listeria monocytogenes into host cell InlB-mediated entry of Listeria monocytogenes into host cell Regulation of signaling by CBL Regulation of signaling by CBL Signaling by CSF1 (M-CSF) in myeloid cells Negative regulation of FLT3 FLT3 signaling by CBL mutants		Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
Novel	CCND2	cyclin D2	Cyclin D associated events in G1 Regulation of RUNX1 Expression and Activity Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) Drug-mediated inhibition of CDK4/CDK6 activity		Testicular cancer
Novel	CD244	CD244 molecule	Cell surface interactions at the vascular wall
Novel	CD44	CD44 molecule (IN blood group)	Degradation of the extracellular matrix Cell surface interactions at the vascular wall Hyaluronan metabolism Integrin cell surface interactions Hyaluronan degradation Neutrophil degranulation Interferon gamma signaling Developmental Lineage of Mammary Gland Luminal Epithelial Cells Developmental Lineage of Mammary Gland Myoepithelial Cells Developmental Lineage of Mammary Stem Cells	Bivatuzumab Hyaluronic acid	Gastric cancer
Novel	CDK4	cyclin dependent kinase 4	SCF(Skp2)-mediated degradation of p27/p21 Oxidative Stress Induced Senescence Senescence-Associated Secretory Phenotype (SASP) Oncogene Induced Senescence RMTs methylate histone arginines Transcriptional regulation of white adipocyte differentiation Cyclin D associated events in G1 Ubiquitin-dependent degradation of Cyclin D Ubiquitin-dependent degradation of Cyclin D PTK6 Regulates Cell Cycle Transcriptional regulation by RUNX2 Meiotic recombination Transcriptional regulation of granulopoiesis Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6 Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6 Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) Drug-mediated inhibition of CDK4/CDK6 activity SPOP-mediated proteasomal degradation of PD-L1(CD274)	Purvalanol Alvocidib Palbociclib Ribociclib Abemaciclib Fostamatinib Trilaciclib	Malignant melanoma Glioma Cervical cancer
Novel	CDK6	cyclin dependent kinase 6	Oxidative Stress Induced Senescence Senescence-Associated Secretory Phenotype (SASP) Oncogene Induced Senescence Cyclin D associated events in G1 Regulation of RUNX1 Expression and Activity Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6 Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6 Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) Drug-mediated inhibition of CDK4/CDK6 activity	Alvocidib (2S)-2-({6-[(3-Amino-5-chlorophenyl)amino]-9-isopropyl-9H-purin-2-yl}amino)-3-methyl-1-butanol Fisetin Palbociclib Ribociclib Abemaciclib Trilaciclib
Novel	CDKN2A	cyclin dependent kinase inhibitor 2A	Oxidative Stress Induced Senescence Senescence-Associated Secretory Phenotype (SASP) Oncogene Induced Senescence Cyclin D associated events in G1 Transcriptional Regulation by VENTX Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6 Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6 Regulation of MITF-M-dependent genes involved in cell cycle and proliferation Apoptotic factor-mediated response Oxidative Stress Induced Senescence Oncogene Induced Senescence SUMOylation of DNA damage response and repair proteins SUMOylation of transcription factors Regulation of TP53 Degradation Stabilization of p53 Regulation of RUNX3 expression and activity Defective Intrinsic Pathway for Apoptosis Due to p14ARF Loss of Function Evasion of Oncogene Induced Senescence Due to p14ARF Defects Evasion of Oxidative Stress Induced Senescence Due to p14ARF Defects Nuclear events mediated by NFE2L2		Chronic myeloid leukemia (CML) Non-small cell lung cancer Malignant islet cell carcinoma Adult T-cell leukemia Esophageal cancer Glioma Pancreatic cancer Nasopharyngeal cancer Hepatocellular carcinoma Squamous cell carcinoma Penile cancer Oral cancer Malignant melanoma Burkitt lymphoma Gallbladder cancer Bladder cancer Laryngeal cancer Cholangiocarcinoma Malignant pleural mesothelioma Osteosarcoma Type II diabetes mellitus
Novel	CDKN2B	cyclin dependent kinase inhibitor 2B	SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription Oxidative Stress Induced Senescence Senescence-Associated Secretory Phenotype (SASP) Oncogene Induced Senescence Cyclin D associated events in G1		Type II diabetes mellitus Osteosarcoma Malignant pleural mesothelioma
Novel	CDKN2C	cyclin dependent kinase inhibitor 2C	Oxidative Stress Induced Senescence Senescence-Associated Secretory Phenotype (SASP) Oncogene Induced Senescence Cyclin D associated events in G1
Novel	CRK	CRK proto-oncogene, adaptor protein	ARMS-mediated activation ARMS-mediated activation Downstream signal transduction Regulation of actin dynamics for phagocytic cup formation p130Cas linkage to MAPK signaling for integrins VEGFA-VEGFR2 Pathway PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases MET activates RAP1 and RAC1 MET receptor recycling Regulation of signaling by CBL FCGR3A-mediated phagocytosis
Novel	CRKL	CRK like proto-oncogene, adaptor protein	Frs2-mediated activation Frs2-mediated activation Downstream signal transduction MET activates RAP1 and RAC1 MET receptor recycling Erythropoietin activates RAS Erythropoietin activates RAS Regulation of signaling by CBL
Novel	EGFR	epidermal growth factor receptor	Signaling by ERBB2 Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants Signaling by ERBB4 SHC1 events in ERBB2 signaling SHC1 events in ERBB2 signaling PLCG1 events in ERBB2 signaling PIP3 activates AKT signaling Signaling by EGFR GRB2 events in EGFR signaling GAB1 signalosome SHC1 events in EGFR signaling EGFR downregulation GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling EGFR interacts with phospholipase C-gamma EGFR Transactivation by Gastrin Constitutive Signaling by Aberrant PI3K in Cancer Signal transduction by L1 Constitutive Signaling by EGFRvIII Inhibition of Signaling by Overexpressed EGFR RAF/MAP kinase cascade ERBB2 Regulates Cell Motility PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling ERBB2 Activates PTK6 Signaling Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis PTK6 promotes HIF1A stabilization Downregulation of ERBB2 signaling TFAP2 (AP-2) family regulates transcription of growth factors and their receptors Extra-nuclear estrogen signaling NOTCH3 Activation and Transmission of Signal to the Nucleus HCMV Early Events Estrogen-dependent nuclear events downstream of ESR-membrane signaling Signaling by ERBB2 KD Mutants Signaling by ERBB2 ECD mutants Signaling by ERBB2 TMD/JMD mutants Respiratory syncytial virus (RSV) attachment and entry Developmental Lineage of Mammary Gland Myoepithelial Cells	Cetuximab Lidocaine Gefitinib Erlotinib Lapatinib Panitumumab Alvocidib IGN311 Matuzumab Vandetanib Rindopepimut Canertinib Pelitinib Varlitinib AV-412 S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE PD-168393 Afatinib Osimertinib Necitumumab Foreskin keratinocyte (neonatal) Depatuxizumab mafodotin Icotinib Neratinib Dacomitinib Fostamatinib Poziotinib Zalutumumab Brigatinib Olmutinib Zanubrutinib Abivertinib Mobocertinib Almonertinib Amivantamab	Laryngeal cancer Cervical cancer Oral cancer Gastric cancer Choriocarcinoma Esophageal cancer Glioma Bladder cancer
Novel	ERBB2	erb-b2 receptor tyrosine kinase 2	Signaling by ERBB2 SHC1 events in ERBB2 signaling SHC1 events in ERBB2 signaling PLCG1 events in ERBB2 signaling PIP3 activates AKT signaling GRB7 events in ERBB2 signaling Downregulation of ERBB2:ERBB3 signaling GRB2 events in ERBB2 signaling GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling Constitutive Signaling by Aberrant PI3K in Cancer Sema4D induced cell migration and growth-cone collapse RAF/MAP kinase cascade ERBB2 Regulates Cell Motility PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling ERBB2 Activates PTK6 Signaling Downregulation of ERBB2 signaling TFAP2 (AP-2) family regulates transcription of growth factors and their receptors Constitutive Signaling by Overexpressed ERBB2 Drug-mediated inhibition of ERBB2 signaling Signaling by ERBB2 KD Mutants Resistance of ERBB2 KD mutants to trastuzumab Resistance of ERBB2 KD mutants to sapitinib Resistance of ERBB2 KD mutants to tesevatinib Resistance of ERBB2 KD mutants to neratinib Resistance of ERBB2 KD mutants to osimertinib Resistance of ERBB2 KD mutants to afatinib Resistance of ERBB2 KD mutants to AEE788 Resistance of ERBB2 KD mutants to lapatinib Signaling by ERBB2 ECD mutants Signaling by ERBB2 TMD/JMD mutants Drug resistance in ERBB2 TMD/JMD mutants Developmental Lineage of Mammary Gland Luminal Epithelial Cells Developmental Lineage of Mammary Gland Myoepithelial Cells Developmental Lineage of Mammary Stem Cells	Trastuzumab Lapatinib IGN311 Trastuzumab emtansine Varlitinib AV-412 Pertuzumab Afatinib Tucatinib Tesevatinib Fostamatinib Brigatinib Margetuximab Zanubrutinib	Breast cancer Cervical cancer Cholangiocarcinoma Pancreatic cancer Gastric cancer Ovarian cancer Choriocarcinoma Endometrial Cancer Bladder cancer

Search Results for: PDGFRA